2nd Annual Pharma Manufacturing & Automation Convention to be held in Hyderabad on Oct 17 & 18
In order to address the gap between the strategic vision and operational realities of the pharma manufacturing sector, Eminence Business Media will be holding the 2nd Annual Pharma Manufacturing & Automation Convention 2019 in Hyderabad on October 17 and 18, 2019.
The past 10 years have been crucial for the Indian pharma landscape. From 2005-2015, the revenue of the top 10 companies grew at 19 percent which is almost at par with the industry growth of 18 percent. Things have significantly changed now with US markets capping prices of crucial drugs that have impacted the overall profit margins.
Indian pharma companies have to nimbly navigate contingencies by expanding the number of FDA approved sites to secure a dominant position in the US market. The US contributes about one-third of the total Indian pharma exports. Furthermore, Indian pharma manufacturing companies accounted for 34 percent of the total ANDA approvals by the US in 2016.
Growth of the Indian pharma industry pivots on crucial parameters like how it responds to the changing scenarios by improving physical capacities, people and organization capacities, and process capability. Indian pharma companies have responded well to the recent scrutiny around quality issues, thus driving significant improvement in manufacturing standards.
To sustain the growth, manufacturing capacities must improve; the industry needs more manpower which leads to more capex on Quality, skills and training. There should be a significant shift towards increasing automation and improved technology transfer along with supply chain maturity and quality assurance for the regulators as well as the end consumers.
The key topics being covered at the convention include Planning new facilities and lines to cater to additional demand while ensuring labor cost advantages are not offset; Reduce tech transfer timelines with more successful commercialization; Increasing automation to have streamlined workflows with fewer handovers and end to end transparency on cost and business values and How automated process control can offer greater flexibility and reassurance to continuous manufacturing.
The past 10 years have been crucial for the Indian pharma landscape. From 2005-2015, the revenue of the top 10 companies grew at 19 percent which is almost at par with the industry growth of 18 percent. Things have significantly changed now with US markets capping prices of crucial drugs that have impacted the overall profit margins.
Indian pharma companies have to nimbly navigate contingencies by expanding the number of FDA approved sites to secure a dominant position in the US market. The US contributes about one-third of the total Indian pharma exports. Furthermore, Indian pharma manufacturing companies accounted for 34 percent of the total ANDA approvals by the US in 2016.
Growth of the Indian pharma industry pivots on crucial parameters like how it responds to the changing scenarios by improving physical capacities, people and organization capacities, and process capability. Indian pharma companies have responded well to the recent scrutiny around quality issues, thus driving significant improvement in manufacturing standards.
To sustain the growth, manufacturing capacities must improve; the industry needs more manpower which leads to more capex on Quality, skills and training. There should be a significant shift towards increasing automation and improved technology transfer along with supply chain maturity and quality assurance for the regulators as well as the end consumers.
The key topics being covered at the convention include Planning new facilities and lines to cater to additional demand while ensuring labor cost advantages are not offset; Reduce tech transfer timelines with more successful commercialization; Increasing automation to have streamlined workflows with fewer handovers and end to end transparency on cost and business values and How automated process control can offer greater flexibility and reassurance to continuous manufacturing.
Comments
Post a Comment